Cytokinetics, Incorporated

Cytokinetics, Incorporated is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Cytokinetics, Incorporated is not a good value stock. Cytokinetics, Incorporated is not a good growth stock. Cytokinetics, Incorporated is not very popular among insiders. Cytokinetics, Incorporated is a mediocre stock to choose.
Log in to see more information.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and devel...
CYTK Fundamental Data by TradingView

News

HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK)
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK)

Ticker Report Cytokinetics (NASDAQ:CYTK - Get Free Report)s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga...\n more…

Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Cantor Fitzgerald
Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Cantor Fitzgerald

Zolmax Cantor Fitzgerald reissued their overweight rating on shares of Cytokinetics (NASDAQ:CYTK - Free Report) in a report released on Monday, Benzinga reports.\nA number of other research firms also...\n more…

Cytokinetics announces data from Phase 1 study of CK-4021586
Cytokinetics announces data from Phase 1 study of CK-4021586

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cytokinetics Announces Data From Phase 1 Study of CK-4021586
Cytokinetics Announces Data From Phase 1 Study of CK-4021586

Globe Newswire Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics...\n more…

Van ECK Associates Corp Buys 1,233 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)
Van ECK Associates Corp Buys 1,233 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Ticker Report Van ECK Associates Corp boosted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent 13F filing with the...\n more…

JPMorgan Chase & Co. Increases Cytokinetics (NASDAQ:CYTK) Price Target to $71.00
JPMorgan Chase & Co. Increases Cytokinetics (NASDAQ:CYTK) Price Target to $71.00

Zolmax Cytokinetics (NASDAQ:CYTK - Free Report) had its price target lifted by JPMorgan Chase Co. from $65.00 to $71.00 in a research note published on Thursday morning, Benzinga reports. JPMorgan...\n more…